AlzChem Group AG

$ 186.00 -0.27 %

AlzChem Group AG operates globally, engaging in the development, production, and distribution of a wide array of chemical products through its subsidiaries. The company's reach extends across Germany, the European Union, the rest of Europe, Asia, the NAFTA region, and other international markets. Its business is organized into three primary divisions: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The diverse product portfolio includes prominent dietary supplements such as Creapure® and Alipure®, along with the creatine-based LIVADUR®. For animal nutrition, AlzChem supplies Creamino®, a guanidinoacetic acid preparation. The pharmaceutical industry benefits from its Bioselect® brand. Industrial applications feature DYHARD® curing agents, acting as accelerators in adhesives, powder coatings, printed circuit boards, and composites, while SILZOT® silicon nitride is vital for ceramics, electronics, and solar technology. The company also manufactures a variety of fine and foundational chemicals, encompassing products derived from calcium carbide, calcium cyanamide (marketed as PERLKA®), hydrogen cyanamide, dicyandiamide, guanidine, guanamines, nitroguanidine, and various aromatic and aliphatic nitriles. Its agricultural offerings include ALZOGUR® germicide for pig pens, Dormex® and Sitofex® plant growth regulators, and BREAK-THRU® plant protection additives. Furthermore, AlzChem provides crucial products for hot metal desulfurization and secondary metallurgy, in addition to technical gases. Beyond its core chemical activities, the group also oversees chemical park operations, offers administrative assistance, and delivers a range of infrastructure services. Established in 1908, AlzChem Group AG maintains its headquarters in Trostberg, Germany.

CEO: Andreas Niedermaier - https://www.alzchem.com

Price objectif

-

Recommandation

-

DCF

$ 104.65

Loading data...

ACT.DE vs S&P500

Loading data...

No data available.

Quick ratio

1.38

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

28.18

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

6.60

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

27.13 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

12.34 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

6.82

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.00

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

3.04

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

27.22 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
4.61 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.50 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.00 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.